Idorsia | Portfolio overview

Key portfolio assets

Compound	Mechanism of action	Target indication	Status	More Information
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, Sweden, and Finland; approved throughout the EU	Investor webcast
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	New data and evaluation of long-term treatment with lucerastat supportive further investigation – regulatory pathway to be discussed with the FDA
Daridorexant	Dual orexin receptor antagonist	Pediatric insomnia	Phase 2 in pediatric insomnia ongoing
IDOR-1117-2520	CCR6 receptor antagonist	Psoriasis	Proof-of-concept study in preparation
ACT-1004-1239	CXCR7 / ACKR3 receptor antagonist	Progressive multiple sclerosis	Proof-of-concept study in preparation
ACT-777991	CXCR3 antagonist	Vitiligo	Proof-of-concept study in preparation

Synthetic Glycan Vaccine Platform			Idorsia will seek a partner for the platform or individual vaccines
IDOR-1134-2831	Synthetic glycan vaccine	Clostridioides difficile infection	Initial Phase 1 data showing safety and immunogenicity

For more information about our portfolio please read our Innovation fact sheet.

Partner-led portfolio

Compound	Mechanism of action	Target indication	Partner: Terms	Status
TRYVIO™ (aprocitentan)	Dual endothelin receptor antagonist	Systemic hypertension in combination with other antihypertensives	In partnership discussions: worldwide development and commercialization rights	Commercially available in the US
JERAYGO™ (aprocitentan)	Dual endothelin receptor antagonist	Resistant hypertension in combination with other antihypertensives	In partnership discussions: worldwide development and commercialization rights	Approved in the EU and UK; Marketing authorization applications submitted in Canada, and Switzerland
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Nxera Pharma: license to develop and commercialize for Asia-Pacific region (excluding China)	Launched for the treatment of insomnia in Japan; Phase 3 ongoing in South Korea
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	Approved for the treatment of insomnia in China and Hong-Kong
Selatogrel	P2Y₁₂ inhibitor	Suspected acute myocardial infarction	Viatris: worldwide development and commercialization rights	Phase 3 “SOS-AMI” program ongoing
Cenerimod	S1P₁ receptor modulator	Systemic lupus erythematosus	Viatris: worldwide development and commercialization rights	Phase 3 “OPUS” program ongoing
Daridorexant	Dual orexin receptor antagonist	Posttraumatic stress disorder (PTSD)	US Department of Defense (DOD): Idorsia supports a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	Phase 2
ACT-1002-4391	EP₂ / EP₄ receptor antagonist	Immuno-oncology	Owkin: global license to develop and commercialize	Phase 1 ongoing